ImmunXperts

Active

Public limited companyfounded 2014active for 12 yearsRue Clément Ader 10, 6041 Charleroi, Belgium36 active companies are registered at this addressKBO/BCE: BE 0552.755.587

Summary

The computed 12-month bankruptcy probability of ImmunXperts is 1.7% (moderate). The 2024 annual accounts show negative equity (-€1.6m) and a net result of -€3.0m. Equity remains stable across the filed financial years (±1.3% per year). Its solvency ranks better than 9% of 241 sector peers (NACE 72, financial year 2024). The company has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

ImmunXpertsActiveChecked score 52/100

Risk analysis Report Compare

Activity

Research and development on biotechnology

NACE 72101

3rd fastest staff growth in Charleroi, Professional and technical services sector1 site

Size

€9.6mtotal assets 2024

Staff: 26.7 FTE
Equity: -€1.6m
Loss: -€3.0m

Financial health

52 Fair Checked score 2024

Bankruptcy probabilitywithin 12 months: 1.7%

Structure

Parent: Nexelis Europe · 100%

Auditor: Forvis Mazars Réviseurs d’Entreprises2025 accounts not filed, 86 days past the deadline

Why 52raises riskLoss of €3.0m, the second in a row (financial year 2024)Negative equity -€1.6mlowers riskSector: Scientific research and development (NACE 72)Liquidity: current ratio 0.46, cash €1.5mShow the evidence

Checked score

Score 2024

52 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 8% of its sector peers (NACE 72, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2023

Weak

Solvency 8-30

equity -16.7% of total assets

Liquidity 20-3

short-term debt 114.9% · cash 15.8%

Profitability 0-46

return on assets -31.1%

Bankruptcy probability, 12 months

1.7% Moderate

0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (165 companies, NACE 72, small)

Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024lowest value 01-2025: 0.5%● unchanged vs 12-2024lowest value 02-2025: 0.5%● unchanged vs 01-2025 03-2025: 0.5%● unchanged vs 02-2025 04-2025: 0.5%● unchanged vs 03-2025 05-2025: 0.6%▲ +0.1 percentage points vs 04-2025 06-2025: 0.6%● unchanged vs 05-2025 07-2025: 0.7%▲ +0.1 percentage points vs 06-2025 08-2025: 1.9%▲ +1.2 percentage points vs 07-2025 09-2025: 1.9%● unchanged vs 08-2025 10-2025: 1.9%● unchanged vs 09-2025 11-2025: 1.9%● unchanged vs 10-2025 12-2025: 1.9%● unchanged vs 11-2025 01-2026: 1.9%● unchanged vs 12-2025 02-2026: 1.9%● unchanged vs 01-2026 03-2026: 1.6%▼ -0.3 percentage points vs 02-2026 04-2026: 1.7%▲ +0.1 percentage points vs 03-2026 05-2026: 1.7%● unchanged vs 04-2026 06-2026: 1.9%▲ +0.2 percentage points vs 05-2026 07-2026: 2.0%▲ +0.1 percentage points vs 06-2026highest value 08-2026: 1.9%▼ -0.1 percentage points vs 07-2026 09-2026: 1.8%▼ -0.1 percentage points vs 08-2026 10-2026: 1.7%▼ -0.1 percentage points vs 09-2026

No credit on open account

Liquidity insufficient (current ratio 0.46, compared with 0.6 in 2023, below 1; short-term debt: 114.9% and cash: 15.8% of total assets), and equity is negative.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 7% on solvency, 14% on liquidity, 11% on profitability and 1% on growth.

The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.

lowers riskraises riskneutral

Loss of €3.0m, the second in a row (financial year 2024)

NBB · annual accounts

Sector: Scientific research and development (NACE 72)

KBO

Negative equity -€1.6m

NBB · annual accounts

Liquidity: current ratio 0.46, cash €1.5m

NBB · annual accounts

Negative equity

The 2024 annual accounts show negative equity and a net loss.

NBB · annual accounts 2024

Equity per financial year

18192021222324

2018 to 2024 · latest year -€1.6m

Annual accounts not filed

The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 86 days later.

NBB · 10 filings

Position against the passed deadline

31-12-2025 year end31-07-2026 deadline25-10-2026 today

Latest accounts filed on time

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 08-07-2025, 23 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

not filed

2024

23 days early

2023

33 days early

2022

16 days late

2021

39 days early

2020

30 days late

2019

9 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 10 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (1)

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

08-01-2026 Appointment: Forvis Mazars Bedrijfsrevisoren - Forvis…Gazette deed
08-07-2025 Annual accounts filedfinancial year 2024 · full…
31-12-2024 Weakest financial yearnet -€3.0m

Key points

Risk: Negative equityfinancial year 2024: debts exceed assets -€1.6m View
Caution: Result fell in 2024from -€266,255 to -€3.0m ▼ 1,018% View
Caution: Among the weakest 5% on equitysector median €1.0m · 241 companies -€1.6m View
Caution: 2025 accounts not fileddeadline was 31-07-2026 86 days past the deadline View
Controlled by Nexelis Europeultimately: Nexelis Group INC. 100% View
Caution: 2 loss-making years in a rowloss financial year 2024 -€3.0m View

By topic

Financials

Financial year: 2024
Total assets: €9.6m
Loss: -€3.0m
Solvency: -16.7%

Total assets▼ 11.7%

Net result

20182024

Go to Financials

Board & ownership

Board: 3 members
Parent: Nexelis Europe · 100%
Auditor: Forvis Mazars Réviseurs d’Entreprises

Clément VanthournhoutDirector
Sofie PATTYNDaily manager
Emmanuel VanderhaegenDirector

Go to Board & ownership

Network & group

Group: Nexelis Group INC.
Connected companies: 38

Go to Network & group

Timeline

Events: 30
Since: 2014

28-06-2024Annual accounts filed
02-02-2024Registered office
16-08-2023Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Public limited company
Activity: Research and development on biotechnologyNACE 72101
Founded: 16-05-2014
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 1

Purpose: “Le développement et la fourniture de services d'analyse ou de prédiction d'effets…” (deed in French)

Go to Articles of association

Key facts about ImmunXperts

What is the company number of ImmunXperts?: 0552.755.587. In Belgium the VAT number is the company number with BE in front: BE 0552.755.587.
Where is ImmunXperts based?: The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does ImmunXperts do?: According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of ImmunXperts?: Public limited company (NV).
When was ImmunXperts founded?: On 16-05-2014.
Is ImmunXperts still active?: Yes, ImmunXperts is an active enterprise in the KBO register.
How many employees does ImmunXperts have?: On average 26.7 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
What is the turnover of ImmunXperts?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is ImmunXperts profitable?: In financial year 2024, ImmunXperts made a loss of €3.0m.
Where can I find the annual accounts of ImmunXperts?: ImmunXperts filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2024.